Source: Benzinga

Bristol-Myers Squibb: Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. Latest Ratings for BMY DateFirmActionFromTo Mar 2022Wells FargoMaintainsEqual-Weight Dec 2021Goldman SachsInitiates Coverage OnBuy Dec 2021Wells FargoInitiates Coverage OnEqual-Weight View More Analyst Ratings for BMY View the Latest Analyst Ratings read more

Read full article »
Bristol-Myers Squibb's Competitors | Bristol-Myers Squibb's News | Bristol-Myers Squibb's Financials
Stay up-to-date with the latest news on Bristol-Myers Squibb
Annual Revenue
$10-50B
Employees
10-50K
Christopher Boerner's photo - CEO of Bristol-Myers Squibb

CEO

Christopher Boerner

CEO Approval Rating

46/100

Read more
Stay up-to-date with the latest news on Bristol-Myers Squibb